Weekly ReportJul 13–19, 2026
Sepsis, week 29 edition
We read 236 papers and selected 3.
Summary
This week’s sepsis literature highlighted a shift toward mechanism-guided precision care, with hepatic immunometabolism, renal perfusion, and cardiomyocyte inflammasome regulation emerging as major therapeutic themes. Two randomized trials showed that physiologic improvement does not necessarily translate into survival benefit: renal resistive index-guided MAP titration improved renal hemodynamics but not mortality, while octenidine cleansing did not prevent neonatal sepsis. Clinically actionable advances included severity-based antibiotic urgency, weekly rezafungin for invasive candidiasis, rapid molecular diagnostics, and improved fluid-responsiveness testing under intra-abdominal hypertension. Large cohorts and multi-omic platforms also advanced risk stratification through atrial fibrillation, lymphopenia, microbiome-metabolome states, and composite biomarkers.
Selected Articles
1. RXRα suppression drives hepatic metabolic and immune dysfunction in sepsis.
This mechanistic study identified hepatocyte retinoid X receptor α (RXRα) as a key regulator of hepatic metabolic stability and antibacterial defense during polymicrobial sepsis. Sepsis rapidly reduced RXRα expression, while hepatocyte-specific RXRα loss depleted Kupffer cells, promoted bacterial dissemination, and increased mortality. Prophylactic, but not therapeutic, bexarotene improved survival in mice, emphasizing the importance of treatment timing.
Impact: The study links hepatocyte transcriptional control to immune-cell niche maintenance and systemic bacterial clearance, revealing a druggable but time-sensitive mechanism of host resilience.
Clinical Implications: RXRα activation may become an early, biomarker-guided strategy to preserve hepatic immune-metabolic function, but human validation, optimal timing, dosing, and safety are required before clinical translation.
Key Findings
- Sepsis rapidly downregulated hepatocyte RXRα under HNF4α regulation.
- Hepatocyte-specific RXRα loss depleted Kupffer cells and promoted bacterial dissemination.
- Prophylactic bexarotene improved survival, whereas therapeutic dosing was ineffective.
2. Renal resistive index-guided mean arterial pressure titration in sepsis: a prospective single-center, single-blind, parallel-group randomized controlled trial.
In a prospective randomized trial of 274 patients with sepsis, renal resistive index-guided MAP titration significantly improved renal hemodynamics compared with conventional treatment. However, 28-day mortality was not significantly reduced, indicating that improvement in a surrogate renal perfusion measure does not necessarily translate into survival benefit.
Impact: This randomized trial directly tests a personalized organ-perfusion strategy and provides important negative evidence against assuming that physiologic target improvement alone improves survival.
Clinical Implications: RRI can be used to monitor renal hemodynamics, but RRI-guided MAP titration should not be adopted solely as a mortality-reducing intervention. Larger multicenter studies should evaluate kidney-specific outcomes and patient selection.
Key Findings
- RRI-guided MAP titration reduced post-treatment RRI compared with conventional care.
- Twenty-eight-day mortality did not differ significantly between groups.
- Improved renal hemodynamics did not translate into a statistically significant survival benefit.
3. Cardiomyocyte-enriched OTUD5 alleviates septic cardiomyopathy by promoting NLRP3 deubiquitination and inhibiting NLRP3 inflammasome activation.
Using cardiomyocyte models and mouse sepsis models, this study identified OTUD5 as a protective deubiquitinase that directly interacts with NLRP3. Cardiomyocyte-specific OTUD5 deficiency worsened pyroptosis, myocardial injury, and cardiac dysfunction, whereas OTUD5 overexpression was protective through an NLRP3-dependent mechanism.
Impact: The study provides rigorous genetic and functional validation of a cardiomyocyte-specific OTUD5–NLRP3 axis, offering a precise molecular explanation for septic cardiomyopathy and a potential therapeutic target.
Clinical Implications: Pharmacologic enhancement of OTUD5 or selective NLRP3 inhibition could eventually reduce septic cardiac injury, but pharmacologic feasibility, toxicity, and human biomarker validation remain unresolved.
Key Findings
- OTUD5 was upregulated in septic myocardial tissue and directly interacted with NLRP3.
- Cardiomyocyte-specific OTUD5 knockout worsened NLRP3-mediated pyroptosis and cardiac injury.
- OTUD5 overexpression lost its protective effect in NLRP3-deficient mice.